Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

GYRE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Gyre Therapeutics, Inc.NASDAQ: GYRE

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 94.6%

Gross margin was 94.6% in Q1 FY2026, down 1.4 pp from a year earlier. On a trailing-twelve-month basis it was 95.1%, down 1.1 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
94.6%-0.8 pp QoQ
Last fiscal yearDec 2025
95.4%-1.0 pp YoY
LTMMar 2026
95.1%-1.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.4 pp——
1 year-1.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
95.4%
Year-over-year change
-1.0pp

Gross Margin vs competitors

How GYRE compares with its peers on the latest reported figures

  • GYRE's LTM Mar 2026 gross margin of 95.1% is the lowest of the 2 companies compared; the peer median is 99.1%.
  • Its year-over-year change of -1.1 pp is the lowest of 2, against a peer median of +2.4 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +10.7 pp.
GYRE Competitors Peer median
Gross Margin for GYRE and competitors
Company Period LTM level YoY 3-year change
SRZNSurrozen, Inc.LTM Mar 202699.1% +2.4 pp+10.7 pp
GYREGyre Therapeutics, Inc.LTM Mar 202695.1% -1.1 pp+0.0 pp
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024— ——
GALTGalectin Therapeutics Inc.FY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
Peer median (excluding GYRE) 99.1%+2.4 pp+10.7 pp

Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.34M102.29M113.45M105.76M116.59M
Cost of Revenue7.67M4.79M4.64M3.88M5.42M
Gross Profit(332K)97.5M108.81M101.87M111.17M
Gross Margin-4.5%95.3%95.9%96.3%95.4%
Research & Development64.57M16.69M13.78M12.02M13.7M
Selling, General & Admin18.82M71.61M75.82M73.62M85.98M
Operating Expenses83.39M88.29M176.04M85.71M99.68M
Depreciation & Amortization290K1.13M1.11M1.59M2.52M
EBITDA(87.64M)10.54M20.33M17.82M16.96M
EBITDA Margin-1194.4%10.3%17.9%16.8%14.5%
Operating Income(83.73M)9.2M(67.23M)16.16M11.49M
Operating Margin-1141.0%9.0%-59.3%15.3%9.9%
Interest Income39K726K1.04M1.55M1.75M
Interest Expense00000
Other Income / Expenses(4.21M)209K(9.74M)7.06M2.95M
Income Before Tax(87.93M)9.41M(76.97M)23.22M14.44M
Pre-Tax Margin-1198.3%9.2%-67.8%22.0%12.4%
Income Tax Expense05.1M8.52M5.32M4.56M
Net Income(87.93M)2.3M(92.93M)12.09M5.03M
Net Margin-1198.3%2.3%-81.9%11.4%4.3%
EPS (Basic)(2.87)0.03(1.41)0.140.06
EPS (Diluted)(2.87)0.03(1.41)0.050.02
Weighted Avg Shares30.64M76.74M65.83M85.09M89.34M
Weighted Avg Shares (Diluted)30.64M75.69M65.83M102.29M103.18M

Gyre Therapeutics, Inc.

NASDAQ:GYRE

Intrinsic Alpha fair value

Locked

Current Price

$4.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.